LONG ISLAND CITY, N.Y.--(BUSINESS WIRE)--HistoWiz, a leading provider of digital histopathology services to academia, biotech and pharma, announced today that Linh Hoang, MD, PhD has been appointed Chief Executive Officer and member of the Board of Directors.
Dr. Hoang is joining HistoWiz from Weavr Health, where he served as CEO and Chairman of the Board of Directors. Prior to Weavr, Linh served as Vice President and General Manager of Reproductive Health Diagnostics at PerkinElmer. He has also held numerous leadership roles at Thermo Fisher Scientific, including General Manager of the clinical controls and standards business and Director for Life Technologies’ personalized medicine initiatives. He was previously a consultant at Boston Consulting Group. Linh received his medical and doctoral degrees from the University of Pennsylvania and holds a bachelor’s in biochemistry from the University of Florida.
“On behalf of the Board, we are pleased to attract Dr. Hoang to the company as the company has nearly doubled revenue in the past year and is poised for continued growth as it furthers its leadership position in the digital pathology field,” said Joseph Siletto, Board Member from Vivo Capital. "We welcome Linh to the HistoWiz team with the confidence that he is not only an experienced operator, but also a strategic thinker to navigate this exciting and rapidly evolving field. We are grateful for our founder Dr. Ke Cheng’s leadership in establishing a strong foundation and look forward to her collaboration with Dr. Hoang both on the board of directors and the senior leadership team.”
“I am proud to join HistoWiz’s accomplished team who has developed a differentiated platform to accelerate research and discovery,” said Dr. Hoang. “I’m looking forward to continuing to work with Dr. Ke Cheng in her role as President and Board Member. I am very excited to grow HistoWiz to lead the digital transformation in research histopathology and believe HistoWiz is well-positioned to become the market leader in histopathology services worldwide.”
HistoWiz automates histopathology with rapid turnaround times for researchers in academia, biotech and pharma. The company utilizes state-of-the-art technologies to process tissue specimens and host the digitized results on a proprietary platform, PathologyMapTM. Researchers use this advanced, online platform to manage their histology data and to collaborate with researchers across the world. With HistoWiz’s AI and proprietary tools, PathologyMap bridges researchers to a network of top pathologists for on-demand interpretation with industry-leading turnaround times. HistoWiz aims to become the global leader in histopathology to accelerate research and discovery.